BACKGROUND: Patients with cytopenia are increasingly undergoing molecular genetic tests of periperal blood or bone marrow for diagnostic purposes. These tests can detect genetic mutations that do not have any morphological correlate in hematologic neoplasia such as myelo - dysplastic syndrome (MDS). A new entity was recently defined to lessen the risk of incorrect diagnoses of MDS. This new entity is a potential precursor of myeloid diseases, analogously to monoclonal gammopathy of undetermined significance as a potential precursor of multiple myeloma. METHODS: This review is based on pertinent articles retrieved by a selective search in PubMed employing the terms "clonal hematopoiesis," "acute myeloid leukemia," and "myelodysplastic syndrome." RESULTS: Clonal hematopoiesis of indeterminate potential (CHIP) is a new entity in which somatic mutations are found in cells of the blood or bone marrow, but no other criteria for hematologic neoplasia are met. Its prevalence rises with age and is roughly 10% among persons aged 70 to 80. It is estimated that, in Germany, about 2.75 million people are affected. The most common mutation is on the DNMT3A gene, followed by TET2 and ASXL1. The rate of transformation to a hematological neoplasia is 0.5-1% per year, and thus about 13 times higher than the incidence of such neoplasias in general. If CHIP is discovered incidentally in a patient with a normal blood count, a complete blood count with differential should be repeated three months later and then at annual intervals. CONCLUSION: CHIP must be included in the differential diagnosis of peripheral blood cytopenia. This new entity can help us understand the clinical significance of clonal hematopoiesis.
BACKGROUND:Patients with cytopenia are increasingly undergoing molecular genetic tests of periperal blood or bone marrow for diagnostic purposes. These tests can detect genetic mutations that do not have any morphological correlate in hematologic neoplasia such as myelo - dysplastic syndrome (MDS). A new entity was recently defined to lessen the risk of incorrect diagnoses of MDS. This new entity is a potential precursor of myeloid diseases, analogously to monoclonal gammopathy of undetermined significance as a potential precursor of multiple myeloma. METHODS: This review is based on pertinent articles retrieved by a selective search in PubMed employing the terms "clonal hematopoiesis," "acute myeloid leukemia," and "myelodysplastic syndrome." RESULTS: Clonal hematopoiesis of indeterminate potential (CHIP) is a new entity in which somatic mutations are found in cells of the blood or bone marrow, but no other criteria for hematologic neoplasia are met. Its prevalence rises with age and is roughly 10% among persons aged 70 to 80. It is estimated that, in Germany, about 2.75 million people are affected. The most common mutation is on the DNMT3A gene, followed by TET2 and ASXL1. The rate of transformation to a hematological neoplasia is 0.5-1% per year, and thus about 13 times higher than the incidence of such neoplasias in general. If CHIP is discovered incidentally in a patient with a normal blood count, a complete blood count with differential should be repeated three months later and then at annual intervals. CONCLUSION: CHIP must be included in the differential diagnosis of peripheral blood cytopenia. This new entity can help us understand the clinical significance of clonal hematopoiesis.
Authors: David P Steensma; Rafael Bejar; Siddhartha Jaiswal; R Coleman Lindsley; Mikkael A Sekeres; Robert P Hasserjian; Benjamin L Ebert Journal: Blood Date: 2015-04-30 Impact factor: 22.113
Authors: John S Welch; Timothy J Ley; Daniel C Link; Christopher A Miller; David E Larson; Daniel C Koboldt; Lukas D Wartman; Tamara L Lamprecht; Fulu Liu; Jun Xia; Cyriac Kandoth; Robert S Fulton; Michael D McLellan; David J Dooling; John W Wallis; Ken Chen; Christopher C Harris; Heather K Schmidt; Joelle M Kalicki-Veizer; Charles Lu; Qunyuan Zhang; Ling Lin; Michelle D O'Laughlin; Joshua F McMichael; Kim D Delehaunty; Lucinda A Fulton; Vincent J Magrini; Sean D McGrath; Ryan T Demeter; Tammi L Vickery; Jasreet Hundal; Lisa L Cook; Gary W Swift; Jerry P Reed; Patricia A Alldredge; Todd N Wylie; Jason R Walker; Mark A Watson; Sharon E Heath; William D Shannon; Nobish Varghese; Rakesh Nagarajan; Jacqueline E Payton; Jack D Baty; Shashikant Kulkarni; Jeffery M Klco; Michael H Tomasson; Peter Westervelt; Matthew J Walter; Timothy A Graubert; John F DiPersio; Li Ding; Elaine R Mardis; Richard K Wilson Journal: Cell Date: 2012-07-20 Impact factor: 41.582
Authors: Peter Valent; Barbara J Bain; John M Bennett; Friedrich Wimazal; Wolfgang R Sperr; Ghulam Mufti; Hans-Peter Horny Journal: Leuk Res Date: 2011-09-13 Impact factor: 3.156
Authors: Giulio Genovese; Anna K Kähler; Robert E Handsaker; Johan Lindberg; Samuel A Rose; Samuel F Bakhoum; Kimberly Chambert; Eran Mick; Benjamin M Neale; Menachem Fromer; Shaun M Purcell; Oscar Svantesson; Mikael Landén; Martin Höglund; Sören Lehmann; Stacey B Gabriel; Jennifer L Moran; Eric S Lander; Patrick F Sullivan; Pamela Sklar; Henrik Grönberg; Christina M Hultman; Steven A McCarroll Journal: N Engl J Med Date: 2014-11-26 Impact factor: 91.245
Authors: Elli Papaemmanuil; Moritz Gerstung; Luca Malcovati; Sudhir Tauro; Gunes Gundem; Peter Van Loo; Chris J Yoon; Peter Ellis; David C Wedge; Andrea Pellagatti; Adam Shlien; Michael John Groves; Simon A Forbes; Keiran Raine; Jon Hinton; Laura J Mudie; Stuart McLaren; Claire Hardy; Calli Latimer; Matteo G Della Porta; Sarah O'Meara; Ilaria Ambaglio; Anna Galli; Adam P Butler; Gunilla Walldin; Jon W Teague; Lynn Quek; Alex Sternberg; Carlo Gambacorti-Passerini; Nicholas C P Cross; Anthony R Green; Jacqueline Boultwood; Paresh Vyas; Eva Hellstrom-Lindberg; David Bowen; Mario Cazzola; Michael R Stratton; Peter J Campbell Journal: Blood Date: 2013-09-12 Impact factor: 22.113
Authors: Nora Chokr; Alexander B Pine; Jan Philipp Bewersdorf; Rory M Shallis; Maximilian Stahl; Amer M Zeidan Journal: Expert Rev Hematol Date: 2019-04-12 Impact factor: 2.929
Authors: Nicholas J Montarello; Mau T Nguyen; Dennis T L Wong; Stephen J Nicholls; Peter J Psaltis Journal: Cardiovasc Drugs Ther Date: 2020-11-10 Impact factor: 3.727